About Nevakar
Nevakar is a company based in New York (United States) founded in 2015 by Navneet Puri. Nevakar has raised $71.09 million across 5 funding rounds from investors including Oxford Finance and H.I.G. Capital. Nevakar offers products and services including NVK002. Nevakar operates in a competitive market with competitors including Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.
- Headquarter New York, United States
- Founders Navneet Puri
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nevakar India Private Limited
- Date of Incorporation 06 Jan, 2020
- Jurisdiction Thane, Maharashtra, India
-
Annual Revenue
$325.54 K (USD)16.29as on Mar 31, 2022
-
Net Profit
$40.09 K (USD)14.75as on Mar 31, 2022
-
EBITDA
$63.48 K (USD)22.64as on Mar 31, 2022
-
Total Equity Funding
$71.09 M (USD)
in 5 rounds
-
Latest Funding Round
$4.59 M (USD), Series C
Aug 08, 2023
-
Investors
Oxford Finance
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nevakar
Nevakar offers a comprehensive portfolio of products and services, including NVK002.
Drug for treating refractive errors through regulatory applications.
People of Nevakar
Unlock access to complete
Unlock access to complete
Funding Insights of Nevakar
Nevakar has successfully raised a total of $71.09M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $4.59 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nevakar
Nevakar has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Oxford Finance and H.I.G. Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked | |
|
Private equity capital is invested in small and mid-sized businesses.
|
Locked | Locked | Locked |
Investor details for Nevakar
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nevakar
Investment portfolio details for Nevakar
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nevakar
Detailed financials for Nevakar
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nevakar Comparisons
Peer comparison for Nevakar
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nevakar
Nevakar operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| Locked | Locked | Locked |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
|
| Locked | Locked | Locked |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized.
|
Detailed competitors of Nevakar
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nevakar
Complete news archive for Nevakar
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nevakar
Nevakar was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Nevakar is headquartered in New York, United States. It is registered at New York, New York, United States.
George Zorich is the current CEO of Nevakar.
Nevakar is a funded company, having raised a total of $71.09M across 5 funding rounds to date.
Annual revenue of Nevakar is $325.54K as on Mar 31, 2022.
Nevakar was established in 2015 in New York, United States, within the pharmaceutical industry. Focus is placed on repositioning FDA-approved molecules to address unmet clinical and commercial needs. Operations involve the creation of novel formulations, improved packaging designs, and alternative drug delivery methods, primarily for injectable and ophthalmic applications. The company is led by founder Navneet Puri and CEO George Zorich.
Nevakar's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Nevakar offers NVK002.
Nevakar has 2 investors. Key investors include Oxford Finance, and H.I.G. Capital.